25 May 2016 - Patented Medicine Prices Review Board releases second edition of flagship report on Canadian public drug plan expenditures.

The Patented Medicine Prices ReviewBoard, through the National Prescription Drug Utilization Information System research initiative, today published the second edition of CompassRx, its flagship annual report that monitors major developments in drug pricing and reimbursement in Canada, analyzes trends, and measures their impact on expenditure levels. Building on the findings of the first edition, CompassRx, 2nd edition focuses on the 2013/14 fiscal year and provides a retrospective review of trends since 2009/10.

For more details, go to: http://pmprb-cepmb.gc.ca/news.asp?a=view&id=183